ARCT 032
Alternative Names: ARCT-032; ARTC032; LUNAR CF - Arcturus Theraepeutics; LUNAR-CF; mRNA CFTR therapeutic - Arcturus TherapeuticsLatest Information Update: 11 Mar 2026
At a glance
- Originator Arcturus Therapeutics
- Developer Arcturus Therapeutics; Cystic Fibrosis Foundation Therapeutics
- Class Antifibrotics; RNA
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants
-
Orphan Drug Status
Yes - Cystic fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 03 Mar 2026 The safety review committee reviews and approves ARCT 032 to proceed into a 12-week phase II trial
- 03 Mar 2026 Arcturus Therapeutics plans a 12-week phase II trial for Cystic fibrosis in USA and other countries (Inhalation), in the first half of 2026
- 22 Oct 2025 Adverse events and efficacy data from a phase II trial in Cystic fibrosis released by Arcturus Therapeutics